Beauty giants target ‘Ozempic face’ as boom in obesity drugs opens new market

By Richa Naidu, Dominique Patton and Alexander Marrow LONDON/PARIS, Oct 21 (Reuters) Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L Oreal are testing treatments for consumers worried about facial sagging and volume loss, looking to capitalise on a growing market tied to the boom in obesity drugs. The companies are targeting concerns known as Ozempic face, a term that emerged as the diabetes drug became widely associated with weight loss. Experts say the loss of facial volume is linked ​to rapid weight loss rather than GLP-1 drugs themselves. GLP-1 drugs, such as Novo Nordisk s Ozempic and Wegovy and Eli Lilly s Zepbound, help people to lose weight ‌by mimicking a hormone that keeps the stomach feeling full. Along with gastrointestinal side effects, the resulting rapid weight loss can also lead to loose skin on the face and body. Pfizer estimates the obesity drug market could reach $150 billion in annual sales by 2030, helping create a potentially